# FERROSAN MEDICAL DEVICES A/S > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/ferrosanmedicaldevices). ## Overview FERROSAN MEDICAL DEVICES A/S is a Denmark-based medical devices company focused on products used to manage bleeding in surgical and other hospital procedures. The business develops, manufactures, and commercializes biomaterial-based hemostatic products and related device solutions through a multi-site operating structure. ## Products & services • Absorbable hemostatic products for bleeding control • Gelatin-based biomaterial devices • Surgical hemostatic matrices and powders • Biomaterial device development and commercialization • Hospital-use bleeding management solutions - **Hemostatic products** (70%) — Absorbable products used to control bleeding during surgery and procedures. - **Biomaterial devices** (20%) — Gelatin-based and other biomaterial device platforms for surgical use. - **Product development** (10%) — Development of new biomaterial device products and related applications. - Absorbable hemostatic products for bleeding control - Gelatin-based biomaterial devices - Surgical hemostatic matrices and powders - Biomaterial device development and commercialization - Hospital-use bleeding management solutions ## Customers The company sells into hospitals and surgical care settings that need dependable bleeding-control products for operating rooms and procedural specialties. Its customer base is primarily healthcare providers and healthcare procurement organizations that buy these products for use in surgery, trauma care, and other invasive procedures. Demand is tied to clinical adoption, hospital purchasing standards, and the need for effective hemostasis in complex procedures. - **Hospitals and hospital systems** (primary) — Buy hemostatic products for routine and complex procedures where bleeding control is critical. - **Surgical departments** (primary) — Use products in operating rooms across cardiovascular, spine, general, and other surgeries. - **Procurement and supply chain organizations** (secondary) — Select products based on clinical performance, availability, and contracting terms. - **Medical distributors** (secondary) — May support access to hospital customers in certain markets and channels. - Hospitals buying hemostatic products for surgery - Operating rooms needing bleeding-control materials - Procurement teams standardizing surgical consumables - Clinicians in specialties with higher bleeding risk - Healthcare systems focused on procedure efficiency ## Geography FERROSAN MEDICAL DEVICES operates from Denmark and reports operational control over two sites, including a site in Poland mentioned in its sustainability disclosures. The available report excerpt does not provide a full revenue-by-country split, so the profile reflects the company’s known Nordic and European operating footprint rather than an exact sales map. - Headquartered in Denmark - Operational control over two sites - One site is located in Poland - Manufacturing and reporting are tied to European operations - No country revenue split disclosed in the excerpt ## Strategy The company’s strategy centers on advancing biomaterial-based device products, including completed and in-progress development projects. It also emphasizes product pipeline development, impairment monitoring of development assets and goodwill, and maintaining operational capacity across its manufacturing footprint. - **Develop biomaterial device products** (medium-term) — New products expand the addressable market and support long-term pipeline value. - **Support surgical hemostasis portfolio** (short-term) — Core products must remain clinically relevant and reliable to retain hospital use. - **Preserve asset value through testing** (short-term) — Development projects, trademarks, and goodwill require regular impairment assessment. - Advance biomaterial device product development - Commercialize products used in surgical bleeding control - Protect and grow value of development assets - Maintain product-level oversight of goodwill and intangibles - Support manufacturing continuity across operating sites ## Risks The main risks are tied to clinical adoption, regulatory certification, and the success of development projects in a specialized medical device market. The company also faces execution risk from manufacturing operations, commodity and energy inputs, and impairment risk if expected product cash flows do not materialize. - **Regulatory and certification limits** [high] — Some uses may fall outside product certifications, which can constrain market access and claims. - **Development project underperformance** [high] — Capitalized development assets depend on future sales and technical success. - **Manufacturing and site disruption** [medium] — Production is concentrated in a small number of controlled sites, increasing operational dependency. - **Hospital demand and procurement pressure** [medium] — Sales depend on hospital budgets, purchasing cycles, and clinical preferences. - Product certification and regulatory compliance risk - Clinical adoption risk for hemostatic products - Development project impairment risk - Manufacturing disruption across operating sites - Demand sensitivity in hospital purchasing ## Accounting The most important accounting issues are the capitalization and impairment of development projects, trademarks, and goodwill, which can materially affect asset values and expense recognition. The annual report also notes changes in sustainability methodology and comparability issues, while financial liabilities and liquidity monitoring make estimates around cash flow and debt maturity relevant for analysis. - **Development project capitalization** — Affects intangible assets and operating profit - **Goodwill impairment** — Can create large non-cash charges - **Value-in-use forecasting** — Highly sensitive to discount rates and sales forecasts - **Sustainability measurement changes** — Affects trend analysis rather than financial statements - Capitalized development projects may later require impairment - Goodwill is tested using value-in-use forecasts - Trademarks and intangibles depend on expected cash flows - Sustainability metric changes reduce year-to-year comparability - Financial liability maturity profiles affect liquidity analysis --- *Last updated: 2026-10-24T15:06:59.708108+00:00*